Stanley Lipkowitz

Ubiquitin Ligase Activity and Tyrosine Phosphorylation Underlie Suppression of Growth Factor Signaling by c-Cbl/Sli-1

Gil Levkowitz, Hadassa Waterman, Seth A. Ettenberg et al. · Molecular Cell · 1999 · 999 citations

Life Sciences, Biochemistry, Molecular Biology +16

Chemotherapy augments TRAIL-induced apoptosis in breast cell lines.

Maccon Keane, Seth A. Ettenberg, Marion M. Nau et al. · PubMed · 1999 · 557 citations

Life Sciences, Oncology, Pharmacology +17

Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study

Jung Min Lee, Ashley Cimino‐Mathews, Cody J. Peer et al. · Journal of Clinical Oncology · 2017 · 240 citations

Medicine, Oncology, Pharmacology +17

The Death Domain Kinase RIP Is Essential for TRAIL (Apo2L)-Induced Activation of IκB Kinase and c-Jun N-Terminal Kinase

Yong Lin, Anne Devin, Amy Cook et al. · Molecular and Cellular Biology · 2000 · 221 citations · Full text

Life Sciences, Cell Biology, Immunology +17

Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study

Erika J. Lampert, Alexandra S. Zimmer, Michelle R. Padget et al. · Clinical Cancer Research · 2020 · 221 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17